703 related articles for article (PubMed ID: 29751586)
21. Telomere maintenance in Wilms tumors: first evidence for the presence of alternative lengthening of telomeres mechanism.
Venturini L; Daidone MG; Motta R; Collini P; Spreafico F; Terenziani M; Piva L; Radice P; Perotti D; Zaffaroni N
Genes Chromosomes Cancer; 2011 Oct; 50(10):823-9. PubMed ID: 21769957
[TBL] [Abstract][Full Text] [Related]
22. Telomerase activity, TERT expression, hTERT promoter alterations, and alternative lengthening of the telomeres (ALT) in meningiomas - a systematic review.
Stögbauer L; Stummer W; Senner V; Brokinkel B
Neurosurg Rev; 2020 Jun; 43(3):903-910. PubMed ID: 30788677
[TBL] [Abstract][Full Text] [Related]
23. Telomerase promoter mutations in cancer: an emerging molecular biomarker?
Vinagre J; Pinto V; Celestino R; Reis M; Pópulo H; Boaventura P; Melo M; Catarino T; Lima J; Lopes JM; Máximo V; Sobrinho-Simões M; Soares P
Virchows Arch; 2014 Aug; 465(2):119-33. PubMed ID: 25048572
[TBL] [Abstract][Full Text] [Related]
24. The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.
Diplas BH; He X; Brosnan-Cashman JA; Liu H; Chen LH; Wang Z; Moure CJ; Killela PJ; Loriaux DB; Lipp ES; Greer PK; Yang R; Rizzo AJ; Rodriguez FJ; Friedman AH; Friedman HS; Wang S; He Y; McLendon RE; Bigner DD; Jiao Y; Waitkus MS; Meeker AK; Yan H
Nat Commun; 2018 May; 9(1):2087. PubMed ID: 29802247
[TBL] [Abstract][Full Text] [Related]
25. Functional Loss of
Graham MK; Kim J; Da J; Brosnan-Cashman JA; Rizzo A; Baena Del Valle JA; Chia L; Rubenstein M; Davis C; Zheng Q; Cope L; Considine M; Haffner MC; De Marzo AM; Meeker AK; Heaphy CM
Mol Cancer Res; 2019 Dec; 17(12):2480-2491. PubMed ID: 31611308
[TBL] [Abstract][Full Text] [Related]
26. Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas.
Ulaner GA; Hoffman AR; Otero J; Huang HY; Zhao Z; Mazumdar M; Gorlick R; Meyers P; Healey JH; Ladanyi M
Genes Chromosomes Cancer; 2004 Oct; 41(2):155-62. PubMed ID: 15287028
[TBL] [Abstract][Full Text] [Related]
27. Alternative lengthening of telomeres in cancer stem cells in vivo.
Bojovic B; Booth RE; Jin Y; Zhou X; Crowe DL
Oncogene; 2015 Jan; 34(5):611-20. PubMed ID: 24531712
[TBL] [Abstract][Full Text] [Related]
28. Telomere biology including TERT rearrangements in neuroblastoma: a useful indicator for surgical treatments.
Kawashima M; Kojima M; Ueda Y; Kurihara S; Hiyama E
J Pediatr Surg; 2016 Dec; 51(12):2080-2085. PubMed ID: 27793328
[TBL] [Abstract][Full Text] [Related]
29. DNA methylation of the TERT promoter and its impact on human cancer.
Lee DD; Komosa M; Nunes NM; Tabori U
Curr Opin Genet Dev; 2020 Feb; 60():17-24. PubMed ID: 32114294
[TBL] [Abstract][Full Text] [Related]
30. Rapid detection of telomerase expression of neuroblastoma in paraffin-embedded tissue: combination of in situ hybridisation and quantitative PCR.
Zhao M; Guan Z; Gong L; Liu F; Gu W; Liu L; Jiang K; Cai J; Feng C; Kuick CH; Chang KTE; Wang J; Tang H; Yin M; Mao J
Pathology; 2023 Dec; 55(7):958-965. PubMed ID: 37741703
[TBL] [Abstract][Full Text] [Related]
31. Selective Elimination of Osteosarcoma Cell Lines with Short Telomeres by Ataxia Telangiectasia and Rad3-Related Inhibitors.
Goncalves T; Zoumpoulidou G; Alvarez-Mendoza C; Mancusi C; Collopy LC; Strauss SJ; Mittnacht S; Tomita K
ACS Pharmacol Transl Sci; 2020 Dec; 3(6):1253-1264. PubMed ID: 33344901
[TBL] [Abstract][Full Text] [Related]
32. Heterogeneity of telomerase reverse transcriptase mutation and expression, telomerase activity and telomere length across human cancer cell lines cultured in vitro.
Dratwa M; Wysoczanska B; Turlej E; Anisiewicz A; Maciejewska M; Wietrzyk J; Bogunia-Kubik K
Exp Cell Res; 2020 Nov; 396(1):112298. PubMed ID: 32971118
[TBL] [Abstract][Full Text] [Related]
33. Alternative Lengthening of Telomeres (ALT) and Telomerase Reverse Transcriptase Promoter Methylation in Recurrent Adult and Primary Pediatric Pituitary Neuroendocrine Tumors.
Alzoubi H; Minasi S; Gianno F; Antonelli M; Belardinilli F; Giangaspero F; Jaffrain-Rea ML; Buttarelli FR
Endocr Pathol; 2022 Dec; 33(4):494-505. PubMed ID: 34993885
[TBL] [Abstract][Full Text] [Related]
34. Telomerase activity in pleural malignant mesotheliomas.
Au AY; Hackl T; Yeager TR; Cohen SB; Pass HI; Harris CC; Reddel RR
Lung Cancer; 2011 Sep; 73(3):283-8. PubMed ID: 21277646
[TBL] [Abstract][Full Text] [Related]
35. Pan-Cancer Analysis of Alternative Lengthening of Telomere Activity.
Sung JY; Lim HW; Joung JG; Park WY
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32784588
[TBL] [Abstract][Full Text] [Related]
36. Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies.
Gao J; Pickett HA
Nat Rev Cancer; 2022 Sep; 22(9):515-532. PubMed ID: 35790854
[TBL] [Abstract][Full Text] [Related]
37. Alternative Lengthening of Telomeres in the Budding Yeast
Cohn M; Andersson AK; Mateo RQ; Möller MC
G3 (Bethesda); 2019 Oct; 9(10):3345-3358. PubMed ID: 31427453
[TBL] [Abstract][Full Text] [Related]
38. Alternative Lengthening of Telomeres and Mediated Telomere Synthesis.
Hou K; Yu Y; Li D; Zhang Y; Zhang K; Tong J; Yang K; Jia S
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565323
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players.
Yuan X; Larsson C; Xu D
Oncogene; 2019 Aug; 38(34):6172-6183. PubMed ID: 31285550
[TBL] [Abstract][Full Text] [Related]
40. High prevalence of TERT aberrations in myxoid liposarcoma: TERT reactivation may play a crucial role in tumorigenesis.
Kunieda J; Yamashita K; Togashi Y; Baba S; Sakata S; Inamura K; Ae K; Matsumoto S; Machinami R; Kitagawa M; Takeuchi K
Cancer Sci; 2022 Mar; 113(3):1078-1089. PubMed ID: 34971481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
